Latest news with #JasemAlNowais
Al Etihad
16-04-2025
- Health
- Al Etihad
M42 launches MENA's first Centre for Advanced Neuro Biochemical Diagnostics
16 Apr 2025 19:53 ABU DHABI (ALETIHAD)The National Reference Laboratory (NRL), part of the M42 Group, is establishing the MENA region's first Centre for Advanced Neuro Biochemical Diagnostics dedicated to early detection, in partnership with Neurocode International, a global leader of neurology diagnostic on the sidelines of Abu Dhabi Global Health Week, the centre, based in Abu Dhabi, is a pioneering step toward reducing Alzheimer's cases in the UAE and wider region, and toward transforming neurological diagnostics disease is a major health issue, affecting over 57 million people globally as of 2021. It is the most common form of dementia, accounting for 60-70 per cent of cases, and this figure is on the detection of Alzheimer's is crucial for managing symptoms and slowing disease progression. However, traditional diagnostic methods are often invasive, typically involving spinal cord needle extraction, which results in low early detection Centre for Advanced Neuro Biochemical Diagnostics aims to revolutionise Alzheimer's diagnosis, by offering screening as early as age 40, through cutting-edge blood-based tests, ensuring timely intervention and significantly improving patient Jasem Al Nowais, Managing Director and Group CEO of M42, said, "This centre will revolutionise the early, proactive detection of Alzheimer's, underscoring our dedication to and the importance of preventive health. By focusing on early intervention, we aim to reduce the impact of Alzheimer's and improve the quality of life for patients in the UAE and beyond."The centre aims to establish the world's most advanced clinical diagnostic laboratory for brain disorders, guiding global clinicians in precision detection and ushering in a new era of neurological diagnostics. Its research will be published in top scientific journals, sharing findings with the wider medical laboratory will also offer world-class technology and clinical infrastructure, ensuring standardised test levels and cut-offs across leading laboratories for consistent, high-quality Laila AbdelWareth, CEO of NRL, said, "The establishment of the Centre for Advanced Neuro Biochemical Diagnostics marks a pivotal moment in the fight against Alzheimer's and other neurological disorders, with a sharp focus on advancing preventive health through precision detection."Expert-led research into neurological diagnostics will be a cornerstone of the Centre for Advanced Neuro Biochemical Diagnostics, with a full-time lab-based professor of neurology with dementia training from Gothenburg University. Prof. Henrik Zetterberg, MD, PhD, expert in the development of biomarkers for Alzheimer's disease and its diagnosis, and Prof. Kaj Blennow, MD, PhD, who is recognised for his instrumental role in developing early diagnostic tools for the disease, will both be off-site expert consultants for the Hans Frykman, CEO of Neurocode International, said, "We are delighted to announce the partnership with the visionary NRL to establish the world's leading clinical laboratory for brain disorders. With a team of the most experienced and renowned scientists in the field, we are poised to guide physicians in the Middle East and globally towards early and accurate diagnoses of Alzheimer's and other brain disorders." The launch marks not only a first for the MENA region but also a new era in global Alzheimer's research. By emphasising proactive prevention, the Centre for Advanced Neuro Biochemical Diagnostics aims to redefine the standard of care and significantly reduce the prevalence of Alzheimer's in the UAE and beyond.
Al Etihad
16-04-2025
- Business
- Al Etihad
M42 announces strategic investment, partnership with leading biotech Juvenescence
16 Apr 2025 17:16 ABU DHABI (ALETIHAD)M42, a global health leader powered by artificial intelligence (AI), technology, and genomics, on Wednesday announced a strategic investment and partnership in longevity biotech leader Juvenescence. The announcement was made during Abu Dhabi Global Health Week (ADGHW), a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care, which is being held from April 15 to 17 at ADNEC, where M42 serves as a Foundational Partner for the second consecutive year. As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening strategic partnership and investment underlines M42's commitment to advancing its capabilities in drug discovery and development, following the creation of its Integrated Health Solutions and Life Sciences platforms under its new, recently announced operating structure. Leveraging M42's deep expertise in genomics, biobanking, and clinical trial infrastructure alongside Juvenescence's cutting-edge AI-enabled discovery technology and extensive drug development expertise, this collaboration will drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organisations globally while supporting the development of M42's biotechnology strategy in Abu Dhabi. A joint steering committee comprised of senior executives from both companies will oversee the execution of this Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, "With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi's push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it's about impact – on lives, on science, and on the future of health.'Dr Fahed Al Marzooqi, Chief Executive Officer of M42's Integrated Health Solutions platform and Acting Chief Executive Officer of M42's AI Life Sciences platform, added, 'Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world.'Dr. Richard Marshall, Chief Executive Officer at Juvenescence, said, 'We are delighted to be working together with M42. This powerful partnership will combine M42's expertise in AI, technology, and genomics with Juvenescence's unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.'The collaboration will see Juvenescence's team of globally recognised scientists and industry leaders - with more than 150 years of cumulative experience in drug discovery and development - work with M42 to build its own innovative therapeutics partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine. M42's Omics Center of Excellence - the largest outside the U.S. - supports the Emirati Genome Project (EGP), which has already sequenced over 800,000 whole genomes and has a goal of sequencing one million local M42's Abu Dhabi Biobank (ADBB) has stored over 900,000 samples, a repository that will be an invaluable resource for future biomedical research in the UAE and beyond. The partnership aligns with Abu Dhabi's broader vision to become a world-class destination for health innovation and to build a life sciences hub as part of its economic diversification agenda.
